1.1. Background: Renal transplantation is the treatment of choice for eligible patients with end-stage renal disease. It provides better outcomes in terms of life expectancy and quality of life than dialysis (Liu, Narins, Maley, Frank, \& Lallas, 2012). Kidney transplants from living donors also have additional benefits in terms of graft function and survival compared to transplants from cadaver donors (Galvani et al., 2012). Living donor transplants provide an opportunity to have good quality grafts and to perform the procedure when the recipient is in an optimal clinical status (Creta et al., 2019). Laparoscopic donor nephrectomy was first introduced in 1995 and is currently accepted as the gold standard for kidney procurement from living donors. The first worldwide robotic assisted laparoscopic donor nephrectomy was performed in 2000 by Horgan et al. (Horgan et al., 2007). The main obstacle to living donation is the exposure of a healthy subject to the risks of a major surgical intervention. Therefore, efforts have been made to reduce complications and postoperative pain, achieve faster recovery, and minimize the surgical incisions. Minimally invasive procedures like hand-assisted and robotic approaches greatly enhance living donation rates, and in 2001 the number of living donors exceeded the number of cadaver donors (Horgan et al., 2007). 1.2. Aim(s)/Objective(s): The objective of this study is to compare intra- and postoperative patient outcomes of kidney donors following hand-assisted and robotic kidney transplants at a single center. 1.3. Rationale for the study: More research is needed regarding the differences between minimally invasive approaches to kidney transplantation.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Patient demographics
Timeframe: between January 2006 and November 2019
Kidney Laterality
Timeframe: between January 2006 and November 2019
operating room (OR) time (minutes)
Timeframe: between January 2006 and November 2019
warm ischemia time (minutes)
Timeframe: between January 2006 and November 2019
estimated blood loss (EBL) (milliliters (mL))
Timeframe: between January 2006 and November 2019
complications (using Clavien-Dindo scale)
Timeframe: between January 2006 and November 2019
hospital length of stay (LOS) (days from admit to discharge)
Timeframe: between January 2006 and November 2019
30-day readmissions
Timeframe: between January 2006 and November 2019
BMI (kilogram per square meter (kg/m^2))
Timeframe: between January 2006 and November 2019
hospital-based charges/costs
Timeframe: between January 2006 and November 2019
creatinine levels at discharge (milligrams per deciliter (mg/dL))
Timeframe: between January 2006 and November 2019